TSL Thinksmart Limited

RNS Number:8547F
Tissue Science Laboratories PLC
01 December 2004



1 December 2004

                        Tissue Science Laboratories Plc 
                     TSL Teach-in For Analysts and Investors

Aldershot, UK - Tissue Science Laboratories plc (LSE: TSL), the medical devices
company specialising in tissue replacement and repair, is holding a teach-in for
analysts and investors today.

In addition to the Company, two guest speakers will be attending and speaking at
the meeting - Professor Norman Williams of the London Hospital and St
Bartholomew's and Dr Paul Sibbons of the Northwick Park Institute of Medical
Research. Professor Williams will be speaking about Permacol's(R) use in
colorectal surgery and stoma repair, from the surgeon's point of view. Dr
Sibbons will be speaking on the potential new applications of Permacol(R) in
orthopaedic and vascular surgery.

Other topics covered throughout the morning will include an in-depth view of the
manufacturing process and science behind TSL's collagen sheet material Permacol
(R), and the current sales operations in General Surgery (complex and recurring
hernia repair) in North America and Europe. Potential future uses of the
technology in other surgical areas will also be discussed.

The teach-in will take place at the London Stock Exchange, 10 Paternoster
Square, London, EC4M 7LS and will commence at 9:30am. For those unable to
attend, presentation slides will be available on request.
                                    
                                      -Ends-

Enquiries:

TSL plc                                        Tel: +44 (0) 1252 333 002
Martin Hunt, Chief Executive
David Jennings, Finance Director


Hogarth PR                                     Tel: +44 (0) 20 7357 9477
Melanie Toyne-Sewell/Kate Catchpole
                                               Mob: +44 (0)790 310 3094


Notes to Editors

Background on TSL

Founded in 1995, with headquarters in Aldershot, Hampshire, TSL is a medical
technology company specialising in tissue repair and replacement with a
proprietary sheet product, derived from porcine dermis, called Permacol(R). TSL
has launched successfully different formulations of the product and built a
development pipeline that addresses the large and fast growing surgical implant
market.  The Company floated in November 2001 and is listed on the Alternative
Investment Market (LSE: TSL).

TSL has a family of products based on the same core technology.  Each product
has been adapted, with unique properties, to make it suitable for use in
different applications, including urology/gynaecology, complex and recurrent
hernia repair, shoulder rotator cuff repair and head and face repair and
reconstruction. The Company has signed distribution agreements with CR Bard Inc
(urology/gynaecology - worldwide), Zimmer Inc (orthopaedic - worldwide) and
Porex Inc (head & face - US and Canada).  Further variations of the sheet and
injectable forms of Permacol(R) are being developed.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCGLBDDXUGGGSB

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Lug 2024 a Ago 2024

Grafico Azioni Thinksmart (LSE:TSL)
Storico
Da Ago 2023 a Ago 2024